Art. -Nr.: HY-N0337

Eugenol,98% (stabilized with TBC)

Name: Eugenol,98% (stabilized with TBC)
Brand: MedChemExpress
SKU: HY-N0337
Price: 25.00 USD
Availability: InStock
Rating: 5 (9 reviews)

9 Cited Publications

Kundenbewertung

Based on 9 publication(s) in Google Scholar

Eugenol is an essential oil found in cloves with antibacterial, anthelmintic and antioxidant activity. Eugenol is shown to inhibit lipid peroxidation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.99%
CAS. Nr.: 97-53-0
Formel: C₁₀H₁₂O₂
Molecular Weight:164.20

Speicherung:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Eugenol,98% (stabilized with TBC) Chemical Structure

CAS. Nr.: 97-53-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (9)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (2)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Eugenol is an essential oil found in cloves with antibacterial, anthelmintic and antioxidant activity. Eugenol is shown to inhibit lipid peroxidation.

IC₅₀ & Target

Bacterial, Parasite^[1]

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	EC₅₀	168 μM Compound: Eugenol	Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay	[PMID: 30878828]
HEK293	EC₅₀	261 μM Compound: Eugenol	Agonist activity at human TRPA1 expressed in HEK293 assessed as increase in calcium influx by two electrode voltage clamp method Agonist activity at human TRPA1 expressed in HEK293 assessed as increase in calcium influx by two electrode voltage clamp method	[PMID: 30878828]
HL-60	IC₅₀	23.7 mM Compound: Eugenol	Antiproliferative activity against human HL60 cells after 2 days by MTT assay Antiproliferative activity against human HL60 cells after 2 days by MTT assay	[PMID: 31195168]
MCF7	IC₅₀	>1500 μM Compound: 28	Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs	[PMID: 36858050]
PC-3	IC₅₀	1 μM Compound: Eugenol	Cytotoxicity against human PC3 cells after 72 hrs by CellTiter one aqueous solution assay Cytotoxicity against human PC3 cells after 72 hrs by CellTiter one aqueous solution assay	[PMID: 31195168]
Peritoneal macrophage	EC₅₀	475.76 μM Compound: 1	Cytotoxicity against BALB/c mouse peritoneal macrophages after 48 hrs by MTT assay Cytotoxicity against BALB/c mouse peritoneal macrophages after 48 hrs by MTT assay	[PMID: 28826085]
RAW264.7	EC₅₀	20.81 μg/mL Compound: Eugenol	Antileishmanial activity against intracellular Leishmania infantum chagasi MHOM/BR/00/1669 amastigotes infected in mouse RAW264.7 cells assessed as inhibition of parasite growth after 48 hrs Antileishmanial activity against intracellular Leishmania infantum chagasi MHOM/BR/00/1669 amastigotes infected in mouse RAW264.7 cells assessed as inhibition of parasite growth after 48 hrs	[PMID: 25281268]
RAW264.7	EC₅₀	56.13 μg/mL Compound: Eugenol	Antileishmanial activity against axenically cultured Leishmania infantum chagasi MHOM/BR/00/1669 promastigotes infected in mouse RAW264.7 cells assessed as inhibition of parasite growth after 48 hrs Antileishmanial activity against axenically cultured Leishmania infantum chagasi MHOM/BR/00/1669 promastigotes infected in mouse RAW264.7 cells assessed as inhibition of parasite growth after 48 hrs	[PMID: 25281268]
RAW264.7	IC₅₀	527.04 μM Compound: 1	Cytotoxicity against mouse RAW264.7 cells after 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 48 hrs by MTT assay	[PMID: 28826085]

In Vitro

The essential oil of O. gratissimum, as well as eugenol, are efficient in inhibiting eclodibility of H. contortus eggs, showing possible utilizations in the treatment of gastrointestinal helmintosis of small ruminants. At 0.50% concentration, the essential oil and eugenol show a maximum eclodibility inhibition^[1]. Eugenol inhibits superoxide anion generation in xanthine-xanthine oxidase system to an extent of 50% at concentrations of 250 μM. Eugenol also inhibits the generation of hydroxyl radicals to an extent of 70%. The OH-radical formation measured by the hydroxylation of salicylate to 2, 3-dihydroxy benzoate is inhibited to an extent of 46% by eugenol at 250 μM^[2]. Eugenol protects against RS-induced development of IBS-like gastrointestinal dysfunction through modulation of HPA-axis and brain monoaminergic pathways apart from its antioxidant effect. Eugenol (50 mg/kg) reduces 80% of RS-induced increase in fecal pellets similar to that of ondansetron. Eugenol attenuates 80% of stress-induced increase in plasma corticosterone and modulates the serotonergic system in the PFC and amygdala. Eugenol attenuates stress-induced changes in norepinephrine and potentiates the antioxidant defense system in all brain regions^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

In Vivo

Eugenol (33 mg/kg) administered orally for 2 days causes significant suppression of knee joint edema, which continues to be significantly reduced at the end of the treatment. After 2 days, eugenol-treated mycobacterial arthritic rats show a marked reduction in paw swelling^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 97-53-0
Appearance Liquid (Density: 1.067 g/cm³)
Molecular Weight 164.20
Formel C₁₀H₁₂O₂
Color Colorless to light yellow
SMILES

OC1=CC=C(CC=C)C=C1OC
Structure Classification
- Phenols
- Monophenols
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (9)

All Cell Proliferation/Viability AssayIn Vivo ImagingHistological Imaging/StainingIn Vivo Efficacy StudyWB

Sort by:

Journal Impact Factor

Autophagy

A/(H1N1) pdm09 NS1 promotes viral replication by enhancing autophagy through hijacking the IAV negative regulatory factor LRPPRC. [Abstract]

2023 May;19(5):1533-1550. PMID: 36300799
Eur J Pharmacol

Eugenol protects against Aspergillus fumigatus keratitis by inhibiting inflammatory response and reducing fungal load. [Abstract]

2022 Jun 5;924:174955. PMID: 35436473

Eugenol,98% (stabilized with TBC) purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Jun 5;924:174955. [Abstract]

Eugenol,98% (stabilized with TBC) (10, 20, 40, 80, 160, 320, 640 μg/mL; 24 h) showed below 320 μg/mL did not affect the intracellular LDH content within 24 h, indicating that eugenol (≤320 μg/mL) had no cytotoxic effect on HCECs.

Eugenol,98% (stabilized with TBC) purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Jun 5;924:174955. [Abstract]

Eugenol,98% (stabilized with TBC) (80, 160, 320 μg/mL; conjunctival sac in mouse right eye 3 times per day for 1, 3, 5 days) showed no ocular lesions were observed on mouse corneas in C57BL/6 mice.

Eugenol,98% (stabilized with TBC) purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Jun 5;924:174955. [Abstract]

Eugenol,98% (stabilized with TBC) (EUG; 160 μg/mL; topically on the right eyes 3 times per day) showed slighter turbidity degree and smaller ulcer areas than those of DMSO-treated group, reduced inflammatory cells infiltration when compared with the control group in mice A.fumigatus keratitis.

Eugenol,98% (stabilized with TBC) purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Jun 5;924:174955. [Abstract]

Eugenol,98% (stabilized with TBC) (EUG; 160 μg/mL; topically on the right eyes 3 times per day) revealed that the corneal fungal load of eugenol-treated mice was less than that of DMSO-treated group in mice A.fumigatus keratitis.

Eugenol,98% (stabilized with TBC) purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Jun 5;924:174955. [Abstract]

Eugenol,98% (stabilized with TBC) (EUG; 160 μg/mL; topically on the right eyes 3 times per day) revealed that mRNA expressions of IL-1β, TNF-α, iNOS were significantly lower in the eugenol-treated group compared with those in DMSO-treated group at 3 days in mice A.fumigatus keratitis.

Eugenol,98% (stabilized with TBC) purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Jun 5;924:174955. [Abstract]

Eugenol,98% (stabilized with TBC) (EUG; 160 μg/mL; topically on the right eyes 3 times per day) increased the protein expressions of Nrf2 at 3 days in mice A.fumigatus keratitis corneas.
Int J Mol Sci

Eugenol Suppresses Platelet Activation and Mitigates Pulmonary Thromboembolism in Humans and Murine Models. [Abstract]

2024 Feb 8;25(4):2098. PMID: 38396774
Microchem J

2026 Feb 9.
ACS Omega

Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]

2024 Feb 28;9(10):11870-11882. PMID: 38496939
Sci Rep

Uncovering Hippo pathway-related biomarkers in acute myocardial infarction via scRNA-seq binding transcriptomics. [Abstract]

2025 Mar 26;15(1):10368. PMID: 40133574
BMC Complement Med Ther

Hepatotoxicity prediction for traditional Chinese medicine: a two-step in silico framework integrating network and machine learning approaches. [Abstract]

2026 Apr 2;26(1):177. PMID: 41923057
Microbiol Spectr

Eugenol works synergistically with colistin against colistin-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae isolates by enhancing membrane permeability. [Abstract]

2023 Sep 14;11(5):e0366622. PMID: 37707450
bioRxiv

2024 Mar 11.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (609.01 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

6.0901 mL

30.4507 mL

60.9013 mL

5 mM

1.2180 mL

6.0901 mL

12.1803 mL

10 mM

0.6090 mL

3.0451 mL

6.0901 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 3.25 mg/mL (19.79 mM); Clear solution

This protocol yields a clear solution of ≥ 3.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (32.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 3.25 mg/mL (19.79 mM); Clear solution

This protocol yields a clear solution of ≥ 3.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (32.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 3.25 mg/mL (19.79 mM); Clear solution

This protocol yields a clear solution of ≥ 3.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (32.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

All Signal Pathway Related

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Pessoa LM, et al. Anthelmintic activity of essential oil of Ocimum gratissimum Linn. and eugenol against Haemonchus contortus. Vet Parasitol. 2002 Oct 16;109(1-2):59-63. [Content Brief]

[2]. Reddy AC, et al. Studies on the inhibitory effects of curcumin and eugenol on the formation of reactive oxygenspecies and the oxidation of ferrous iron. Mol Cell Biochem. 1994 Aug 17;137(1):1-8. [Content Brief]

[3]. Garabadu D, et al. Protective effect of eugenol against restraint stress-induced gastrointestinal dysfunction: Potential use in irritable bowel syndrome. Pharm Biol. 2015 Jul;53(7):968-74. [Content Brief]

[4]. Sharma JN, et al. Suppressive effects of eugenol and ginger oil on arthritic rats. Pharmacology. 1994 Nov;49(5):314-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	6.0901 mL	30.4507 mL	60.9013 mL	152.2534 mL
	5 mM	1.2180 mL	6.0901 mL	12.1803 mL	30.4507 mL
	10 mM	0.6090 mL	3.0451 mL	6.0901 mL	15.2253 mL
	15 mM	0.4060 mL	2.0300 mL	4.0601 mL	10.1502 mL
	20 mM	0.3045 mL	1.5225 mL	3.0451 mL	7.6127 mL
	25 mM	0.2436 mL	1.2180 mL	2.4361 mL	6.0901 mL
	30 mM	0.2030 mL	1.0150 mL	2.0300 mL	5.0751 mL
	40 mM	0.1523 mL	0.7613 mL	1.5225 mL	3.8063 mL
	50 mM	0.1218 mL	0.6090 mL	1.2180 mL	3.0451 mL
	60 mM	0.1015 mL	0.5075 mL	1.0150 mL	2.5376 mL
	80 mM	0.0761 mL	0.3806 mL	0.7613 mL	1.9032 mL
	100 mM	0.0609 mL	0.3045 mL	0.6090 mL	1.5225 mL

Bioz

Keywords

Eugenol,98% (stabilized with TBC)

9 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Eugenol,98% (stabilized with TBC)

Publications Citing Use of MedChemExpress (MCE) Eugenol,98% (stabilized with TBC)

Alle Parasite Isoform-spezifische Produkte anzeigen